.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
US Department of Justice
Cipla
Healthtrust
Johnson and Johnson
Boehringer Ingelheim
McKesson
Argus Health
Queensland Health
Colorcon

Generated: November 24, 2017

DrugPatentWatch Database Preview

KAPVAY Drug Profile

« Back to Dashboard

What is the patent landscape for Kapvay, and when can generic versions of Kapvay launch?

Kapvay is a drug marketed by Concordia Pharms Inc and is included in one NDA.

The generic ingredient in KAPVAY is clonidine hydrochloride. There are twenty-two drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the clonidine hydrochloride profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-003Sep 28, 2010AB1RXYesYes► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-004Sep 28, 2010DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: KAPVAY

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-003Sep 28, 2010► Subscribe► Subscribe
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-004Sep 28, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for KAPVAY

Drugname Dosage Strength RLD Submissiondate
clonidine hydrochlorideExtended-release Tablets0.1 mg and 0.2 mgKapvay3/4/2011
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Deloitte
Julphar
Daiichi Sankyo
Accenture
Fuji
Chinese Patent Office
Fish and Richardson
Cipla
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot